IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma
ABSTRACT: Type-2 inflammation is the most frequent endophenotype of asthma. Different biomarkers have been proposed to identify this inflammation because highly effective therapies have improved type-2 severe asthma control. We investigated the frequency of some biomarkers of type-2 inflammation (to...
- Autores:
-
Sánchez Caraballo, Jorge Mario
Morales Cárdenas, Edison
Santamaría Salazar, Luis Carlos
Acevedo Vásquez, Ana Milena
Calle Álvarez, Ana María
Olivares Gómez, María Margarita
Gómez García, Carolina
Amaya Ruiz, Emerson Daniel
Cardona Villa, Ricardo
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2021
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/45014
- Acceso en línea:
- https://hdl.handle.net/10495/45014
- Palabra clave:
- Asma
Asthma
Biomarcadores
Biomarkers
Eosinófilos
Eosinophils
Inmunoglobulina E
Immunoglobulin E
Terapia Biológica
Biological Therapy
Prueba de Óxido Nítrico Exhalado Fraccionado
Fractional Exhaled Nitric Oxide Testing
https://id.nlm.nih.gov/mesh/D001249
https://id.nlm.nih.gov/mesh/D015415
https://id.nlm.nih.gov/mesh/D004804
https://id.nlm.nih.gov/mesh/D007073
https://id.nlm.nih.gov/mesh/D001691
https://id.nlm.nih.gov/mesh/D000089142
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/2.5/co/
| id |
UDEA2_9c9c9bdb495b660f97ef8a046c842f0e |
|---|---|
| oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/45014 |
| network_acronym_str |
UDEA2 |
| network_name_str |
Repositorio UdeA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma |
| title |
IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma |
| spellingShingle |
IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma Asma Asthma Biomarcadores Biomarkers Eosinófilos Eosinophils Inmunoglobulina E Immunoglobulin E Terapia Biológica Biological Therapy Prueba de Óxido Nítrico Exhalado Fraccionado Fractional Exhaled Nitric Oxide Testing https://id.nlm.nih.gov/mesh/D001249 https://id.nlm.nih.gov/mesh/D015415 https://id.nlm.nih.gov/mesh/D004804 https://id.nlm.nih.gov/mesh/D007073 https://id.nlm.nih.gov/mesh/D001691 https://id.nlm.nih.gov/mesh/D000089142 |
| title_short |
IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma |
| title_full |
IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma |
| title_fullStr |
IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma |
| title_full_unstemmed |
IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma |
| title_sort |
IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma |
| dc.creator.fl_str_mv |
Sánchez Caraballo, Jorge Mario Morales Cárdenas, Edison Santamaría Salazar, Luis Carlos Acevedo Vásquez, Ana Milena Calle Álvarez, Ana María Olivares Gómez, María Margarita Gómez García, Carolina Amaya Ruiz, Emerson Daniel Cardona Villa, Ricardo |
| dc.contributor.author.none.fl_str_mv |
Sánchez Caraballo, Jorge Mario Morales Cárdenas, Edison Santamaría Salazar, Luis Carlos Acevedo Vásquez, Ana Milena Calle Álvarez, Ana María Olivares Gómez, María Margarita Gómez García, Carolina Amaya Ruiz, Emerson Daniel Cardona Villa, Ricardo |
| dc.contributor.researchgroup.spa.fl_str_mv |
Grupo de Alergología Clínica y Experimental (GACE) |
| dc.subject.decs.none.fl_str_mv |
Asma Asthma Biomarcadores Biomarkers Eosinófilos Eosinophils Inmunoglobulina E Immunoglobulin E Terapia Biológica Biological Therapy Prueba de Óxido Nítrico Exhalado Fraccionado Fractional Exhaled Nitric Oxide Testing |
| topic |
Asma Asthma Biomarcadores Biomarkers Eosinófilos Eosinophils Inmunoglobulina E Immunoglobulin E Terapia Biológica Biological Therapy Prueba de Óxido Nítrico Exhalado Fraccionado Fractional Exhaled Nitric Oxide Testing https://id.nlm.nih.gov/mesh/D001249 https://id.nlm.nih.gov/mesh/D015415 https://id.nlm.nih.gov/mesh/D004804 https://id.nlm.nih.gov/mesh/D007073 https://id.nlm.nih.gov/mesh/D001691 https://id.nlm.nih.gov/mesh/D000089142 |
| dc.subject.meshuri.none.fl_str_mv |
https://id.nlm.nih.gov/mesh/D001249 https://id.nlm.nih.gov/mesh/D015415 https://id.nlm.nih.gov/mesh/D004804 https://id.nlm.nih.gov/mesh/D007073 https://id.nlm.nih.gov/mesh/D001691 https://id.nlm.nih.gov/mesh/D000089142 |
| description |
ABSTRACT: Type-2 inflammation is the most frequent endophenotype of asthma. Different biomarkers have been proposed to identify this inflammation because highly effective therapies have improved type-2 severe asthma control. We investigated the frequency of some biomarkers of type-2 inflammation (total IgE, sIgE, blood eosinophil, and FeNO) in the framework of severe asthma and assessed its ability to help us to choose the best biological therapy for each patient. Different scenarios (sensitivity analysis) were evaluated according to the biomarkers proposed for each biological therapy in 72 patients with type-2 severe asthma. Between 54.1% and 68% of patients could receive at least 2 different biological therapies and 34.7%-40.2% could receive any of the 3 types of therapies (anti-IgE, anti-eosinophil, anti-IL4). Biomarkers help to identify type-2 severe asthma but total IgE, sIgE, blood eosinophil, and FeNO are not enough to select 1 specific therapy. With the increasing arrival of new biological therapies, it is necessary to identify new biomarkers that allow us to improve our selection criteria for the best therapy for each patient or to construct a prediction rule. |
| publishDate |
2021 |
| dc.date.issued.none.fl_str_mv |
2021 |
| dc.date.accessioned.none.fl_str_mv |
2025-02-19T16:30:57Z |
| dc.date.available.none.fl_str_mv |
2025-02-19T16:30:57Z |
| dc.type.spa.fl_str_mv |
Artículo de investigación |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ART |
| dc.type.coarversion.spa.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| status_str |
publishedVersion |
| dc.identifier.citation.spa.fl_str_mv |
Sánchez J, Morales E, Santamaria LC, Acevedo AM, Calle A, Olivares M, Gómez C, Amaya D, Cardona R. IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma. World Allergy Organ J. 2021 Mar 5;14(3):100520. doi: 10.1016/j.waojou.2021.100520. |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/10495/45014 |
| dc.identifier.doi.none.fl_str_mv |
10.1016/j.waojou.2021.100520 |
| dc.identifier.eissn.none.fl_str_mv |
1939-4551 |
| identifier_str_mv |
Sánchez J, Morales E, Santamaria LC, Acevedo AM, Calle A, Olivares M, Gómez C, Amaya D, Cardona R. IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma. World Allergy Organ J. 2021 Mar 5;14(3):100520. doi: 10.1016/j.waojou.2021.100520. 10.1016/j.waojou.2021.100520 1939-4551 |
| url |
https://hdl.handle.net/10495/45014 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
World. Allergy. Organ. J. |
| dc.relation.citationendpage.spa.fl_str_mv |
5 |
| dc.relation.citationissue.spa.fl_str_mv |
3 |
| dc.relation.citationstartpage.spa.fl_str_mv |
1 |
| dc.relation.citationvolume.spa.fl_str_mv |
14 |
| dc.relation.ispartofjournal.spa.fl_str_mv |
World Allergy Organization Journal |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ https://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
5 páginas |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Elsevier |
| dc.publisher.place.spa.fl_str_mv |
Atlanta, Estados Unidos |
| institution |
Universidad de Antioquia |
| bitstream.url.fl_str_mv |
https://bibliotecadigital.udea.edu.co/bitstreams/03b57465-d379-42f9-a23d-6387623a45ae/download https://bibliotecadigital.udea.edu.co/bitstreams/b8152a51-2dd2-49cc-b097-a4896bd31d68/download https://bibliotecadigital.udea.edu.co/bitstreams/17139bd7-b359-48a5-9725-8e0899cbcf58/download https://bibliotecadigital.udea.edu.co/bitstreams/c29834f1-eaa2-433e-b343-b34b795e064e/download https://bibliotecadigital.udea.edu.co/bitstreams/cc7d3cdb-bdc7-44ac-8614-d19261b0bbfc/download |
| bitstream.checksum.fl_str_mv |
cec7f94b3919e7d00bc0e9fdcfef8d94 b88b088d9957e670ce3b3fbe2eedbc13 8a4605be74aa9ea9d79846c1fba20a33 8012856b44a7c46ec255c7a136484cc6 e7379115c53639ea234c445a9f0d8715 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional de la Universidad de Antioquia |
| repository.mail.fl_str_mv |
aplicacionbibliotecadigitalbiblioteca@udea.edu.co |
| _version_ |
1851052481530822656 |
| spelling |
Sánchez Caraballo, Jorge MarioMorales Cárdenas, EdisonSantamaría Salazar, Luis CarlosAcevedo Vásquez, Ana MilenaCalle Álvarez, Ana MaríaOlivares Gómez, María MargaritaGómez García, CarolinaAmaya Ruiz, Emerson DanielCardona Villa, RicardoGrupo de Alergología Clínica y Experimental (GACE)2025-02-19T16:30:57Z2025-02-19T16:30:57Z2021Sánchez J, Morales E, Santamaria LC, Acevedo AM, Calle A, Olivares M, Gómez C, Amaya D, Cardona R. IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma. World Allergy Organ J. 2021 Mar 5;14(3):100520. doi: 10.1016/j.waojou.2021.100520.https://hdl.handle.net/10495/4501410.1016/j.waojou.2021.1005201939-4551ABSTRACT: Type-2 inflammation is the most frequent endophenotype of asthma. Different biomarkers have been proposed to identify this inflammation because highly effective therapies have improved type-2 severe asthma control. We investigated the frequency of some biomarkers of type-2 inflammation (total IgE, sIgE, blood eosinophil, and FeNO) in the framework of severe asthma and assessed its ability to help us to choose the best biological therapy for each patient. Different scenarios (sensitivity analysis) were evaluated according to the biomarkers proposed for each biological therapy in 72 patients with type-2 severe asthma. Between 54.1% and 68% of patients could receive at least 2 different biological therapies and 34.7%-40.2% could receive any of the 3 types of therapies (anti-IgE, anti-eosinophil, anti-IL4). Biomarkers help to identify type-2 severe asthma but total IgE, sIgE, blood eosinophil, and FeNO are not enough to select 1 specific therapy. With the increasing arrival of new biological therapies, it is necessary to identify new biomarkers that allow us to improve our selection criteria for the best therapy for each patient or to construct a prediction rule.COL00595675 páginasapplication/pdfengElsevierAtlanta, Estados Unidoshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthmaArtículo de investigaciónhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionAsmaAsthmaBiomarcadoresBiomarkersEosinófilosEosinophilsInmunoglobulina EImmunoglobulin ETerapia BiológicaBiological TherapyPrueba de Óxido Nítrico Exhalado FraccionadoFractional Exhaled Nitric Oxide Testinghttps://id.nlm.nih.gov/mesh/D001249https://id.nlm.nih.gov/mesh/D015415https://id.nlm.nih.gov/mesh/D004804https://id.nlm.nih.gov/mesh/D007073https://id.nlm.nih.gov/mesh/D001691https://id.nlm.nih.gov/mesh/D000089142World. Allergy. Organ. J.53114World Allergy Organization JournalPublicationORIGINALSanchezJorge_2021_IgE_Blood_Eosinophils.pdfSanchezJorge_2021_IgE_Blood_Eosinophils.pdfArtículo de investigaciónapplication/pdf371144https://bibliotecadigital.udea.edu.co/bitstreams/03b57465-d379-42f9-a23d-6387623a45ae/downloadcec7f94b3919e7d00bc0e9fdcfef8d94MD51trueAnonymousREADCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8823https://bibliotecadigital.udea.edu.co/bitstreams/b8152a51-2dd2-49cc-b097-a4896bd31d68/downloadb88b088d9957e670ce3b3fbe2eedbc13MD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/17139bd7-b359-48a5-9725-8e0899cbcf58/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADTEXTSanchezJorge_2021_IgE_Blood_Eosinophils.pdf.txtSanchezJorge_2021_IgE_Blood_Eosinophils.pdf.txtExtracted texttext/plain16305https://bibliotecadigital.udea.edu.co/bitstreams/c29834f1-eaa2-433e-b343-b34b795e064e/download8012856b44a7c46ec255c7a136484cc6MD54falseAnonymousREADTHUMBNAILSanchezJorge_2021_IgE_Blood_Eosinophils.pdf.jpgSanchezJorge_2021_IgE_Blood_Eosinophils.pdf.jpgGenerated Thumbnailimage/jpeg17164https://bibliotecadigital.udea.edu.co/bitstreams/cc7d3cdb-bdc7-44ac-8614-d19261b0bbfc/downloade7379115c53639ea234c445a9f0d8715MD55falseAnonymousREAD10495/45014oai:bibliotecadigital.udea.edu.co:10495/450142025-03-26 23:02:21.155http://creativecommons.org/licenses/by-nc-nd/2.5/co/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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 |
